Actively Recruiting
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-12-11
30
Participants Needed
1
Research Sites
400 weeks
Total Duration
On this page
Sponsors
C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor
B
Beijing Jishuitan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.
CONDITIONS
Official Title
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 18 years
- Histologically confirmed soft tissue sarcoma of trunk or extremity suitable for preoperative radiotherapy and conservative surgery
- ECOG performance status of 0 to 3
- Histology reviewed by a reference pathologist
- Lesion can be assessed
- Able to tolerate radiotherapy and Anlotinib treatment
- Agree to use contraception
- Signed informed consent indicating understanding of the study and its risks
You will not qualify if you...
- No gross tumor remaining after prior surgery at another center
- Contraindications to Anlotinib, including allergy, active bleeding, ulcers, enteric perforation or obstruction, uncontrolled hypertension, severe heart failure, or severe liver or kidney problems
- Diagnosis of dermatofibrosarcoma protuberans, desmoids, or benign tumors
- Secondary cancer within the past 5 years (except cervical carcinoma in situ or early-stage skin basal cell carcinoma)
- Soft tissue sarcoma curable by extensive surgery alone
- Previous radiation to the same area
- Evidence of distant metastases on imaging
- Other contraindications or inability to tolerate surgery or study treatments
- Neoadjuvant chemotherapy given or planned
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
N
Ning-Ning Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here